Rohit Duggal

Rohit Duggal

Corporate Officer/Principal bij ONK Therapeutics Ltd.

Health Technology

Oorsprong van het eerstegraads netwerk van Rohit Duggal

EntiteitType entiteitIndustrie
10
Holding Company Biotechnology 10

Grafiek van bedrijven verbonden in de tweede graad

Connectie in verschillende bedrijven

Bedrijven verbonden met Rohit Duggal via zijn persoonlijke netwerk

OndernemingSectorGelieerde personenHoofdpost
Pharmaceuticals: Major

Andrew Phillips

Raymond Kelleher

Director/Board Member

Director/Board Member

Medical Specialties

Andrew Phillips

Raymond Kelleher

Director/Board Member

Director/Board Member

Investment Managers

Andrew Phillips

Raymond Kelleher

Private Equity Investor

Private Equity Investor

Loyola University of Chicago College/University

Hugh O'Dowd

Undergraduate Degree

Biotechnology

Andrew Phillips

Director/Board Member

MOONLAKE IMMUNOTHERAPEUTICS Pharmaceuticals: Major

Andrew Phillips

Director/Board Member

Biotechnology

Andrew Phillips

Chief Executive Officer

Aleksia Therapeutics, Inc.

Andrew Phillips

Chief Executive Officer

Blossom Biomedicines USA, Inc.

Andrew Phillips

Director/Board Member

Miscellaneous Commercial Services

Andrew Phillips

Director/Board Member

Pharmaceuticals: Major

Andrew Phillips

Director/Board Member

Pharmaceuticals: Major

Andrew Phillips

Founder

The University of Colorado College/University

Andrew Phillips

Corporate Officer/Principal

ENLIVEN THERAPEUTICS, INC. Biotechnology

Andrew Phillips

Director/Board Member

NEON THERAPEUTICS, INC. Biotechnology

Hugh O'Dowd

Chief Executive Officer

AVANTOGEN ONCOLOGY, INC. Pharmaceuticals: Major

Christopher Nowers

Chief Executive Officer

Biotechnology

Andrew Phillips

Corporate Officer/Principal

Pharmaceuticals: Major

Hugh O'Dowd

Corporate Officer/Principal

Pharmaceuticals: Major

Hugh O'Dowd

President

Pharmaceuticals: Major

Hugh O'Dowd

Corporate Officer/Principal

PUMA BIOTECHNOLOGY, INC. Pharmaceuticals: Major

Hugh O'Dowd

Director/Board Member

Novartis Ireland Ltd.

Hugh O'Dowd

President

THERAPEUTICSMD, INC. Pharmaceuticals: Major

Hugh O'Dowd

Chief Executive Officer

SPEXIS AG Pharmaceuticals: Major

Hugh O'Dowd

Director/Board Member

Pharmaceuticals: Major

Raymond Kelleher

Director/Board Member

Massachusetts Institute of Technology College/University

Raymond Kelleher

Undergraduate Degree

College/University

Raymond Kelleher

Graduate Degree

Stanford University College/University

Raymond Kelleher

Doctorate Degree

Biotechnology

Raymond Kelleher

Director/Board Member

Biotechnology

Raymond Kelleher

Director/Board Member

Kellstadt Graduate School of Business College/University

Hugh O'Dowd

Masters Business Admin

Yale University College/University

Andrew Phillips

Corporate Officer/Principal

KITE PHARMA INC Biotechnology

Christopher Nowers

Corporate Officer/Principal

FOGHORN THERAPEUTICS INC. Biotechnology

Allan Reine

Director of Finance/CFO

GENOMIC HEALTH, INC. Medical Specialties

Christopher Nowers

Sales & Marketing

AMGEN INC. Pharmaceuticals: Major

Christopher Nowers

Corporate Officer/Principal

Pharmaceuticals: Major

Christopher Nowers

Chief Executive Officer

University of Western Ontario College/University

Allan Reine

Undergraduate Degree

University of Toronto College/University

Allan Reine

Doctorate Degree

Investment Managers

Allan Reine

Portfolio Manager-Equities

Investment Managers

Allan Reine

Portfolio Manager-Equities

PIERIS PHARMACEUTICALS, INC. Biotechnology

Allan Reine

Director of Finance/CFO

Cormorantasset Management LP

Andrew Phillips

Corporate Officer/Principal

PRIME MEDICINE, INC. Biotechnology

Allan Reine

Director of Finance/CFO

Statistieken

Internationaal

Verenigde Staten 40
Zwitserland 4
Verenigd Koninkrijk 4
Canada 3
Hongkong 2

Sectoraal

Health Technology 28
Finance 11
Consumer Services 9
Commercial Services 2

Operationeel

Director/Board Member 34
Corporate Officer/Principal 13
Chief Executive Officer 10
President 7
Founder 6
  1. Beurs
  2. Insiders
  3. Rohit Duggal
  4. Bedrijfsconnecties
-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU